| __timestamp | BioCryst Pharmaceuticals, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 125883000 |
| Thursday, January 1, 2015 | 1896000 | 69036000 |
| Friday, January 1, 2016 | 2699000 | 72700000 |
| Sunday, January 1, 2017 | 1702000 | 105700000 |
| Monday, January 1, 2018 | 471000 | 198700000 |
| Tuesday, January 1, 2019 | 4101000 | 117600000 |
| Wednesday, January 1, 2020 | 1676000 | 108100000 |
| Friday, January 1, 2021 | 7264000 | 122500000 |
| Saturday, January 1, 2022 | 6594000 | 146700000 |
| Sunday, January 1, 2023 | 4661000 | 257500000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for United Therapeutics Corporation and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Over this period, United Therapeutics consistently reported higher costs, peaking in 2023 with a staggering 257% increase from its 2015 low. In contrast, BioCryst Pharmaceuticals exhibited more volatility, with costs fluctuating significantly, reaching their zenith in 2021. Notably, BioCryst's cost of revenue in 2023 was approximately 64% lower than United Therapeutics, highlighting a stark contrast in operational scale and strategy. These insights underscore the diverse financial landscapes within the pharmaceutical sector, offering a window into each company's strategic priorities and market positioning.
Cost of Revenue Trends: Sanofi vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and United Therapeutics Corporation
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: United Therapeutics Corporation vs PTC Therapeutics, Inc.
Cost of Revenue Trends: United Therapeutics Corporation vs HUTCHMED (China) Limited
Key Insights on Gross Profit: United Therapeutics Corporation vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Vericel Corporation vs BioCryst Pharmaceuticals, Inc.